趋化因子是一类能趋化免疫细胞定向移动的小分子分泌蛋白。趋化因子CCL19和其受体CCR7在树突状细胞、T细胞和多种肿瘤细胞上表达。近年来，CCL19及CCR7在抗肿瘤治疗中的作用成为研究热点并取得显著进展，它们在趋化树突状细胞、CD4+和CD8+ T细胞浸润肿瘤,介导免疫细胞释放细胞因子,抑制肿瘤增殖、迁移和侵袭以及协助治疗肿瘤过程中发挥关键作用，对其深入研究有助于找到新的肿瘤治疗手段和基因疫苗。该文对CCL19在介导免疫细胞抗肿瘤中的作用作一综述。

Chemokines are a family of small cytokines secreted by immune cells, which act as a chemoattractant to guide the migration of immune cells. It has been reported that CCL19 (chemokine C-C motif ligand 19) and its receptor CCR7 (a seven transmembrane protein) are expressed in dendritic cells, CD4+ and CD8+T cells and variety of tumor cells. Recently, more attention has been focused on the antitumor effect of CCL19 and its receptor CCR7, which has been well-documented in the literature and was vital to attracting dendritic cells, infiltration of tumors by CD4+ and CD8+T cells, mediating immune cells to release cytokines, inhibiting the proliferation, invasion, and migration of tumors, and assisting the treatment of tumors. Further studies on CCL19 and CCR7 are helpful for developing new treatments of tumors and gene vaccines. This paper reviews the role of CCL19 the immune cell mediated antitumor therapy.